Abstract
CPT-11 (irinotecan), a DNA topoisomerase I inhibitor is one of the main treatments for colorectal cancer. The main dose limiting toxicities are neutropenia and late onset diarrhea. Though neutropenia is manageable, CPT-11 induced diarrhea is frequently severe, resulting in hospitalizations, dose reductions or omissions leading to ineffective treatment administration. Many potential agents have been tested in preclinical and clinical studies to prevent or ameliorate CPT-11 induced late onset diarrhea. It is predicted that prophylaxis of CPT-11 induced diarrhea will reduce sub-therapeutic dosing as well as hospitalizations and will eventually lead to dose escalations resulting in better response rates. This article reviews various experimental agents and strategies employed to prevent this debilitating toxicity. Covered topics include schedule/dose modification, intestinal alkalization, structural/chemical modification, genetic testing, anti-diarrheal therapies, transporter (ABCB1, ABCC2, BCRP2) inhibitors, enzyme (β-glucuronidase, UGT1A1, CYP3A4, carboxylesterase, COX-2) inducers and inhibitors, probiotics, antibiotics, adsorbing agents, cytokine and growth factor activators and inhibitors and other miscellaneous agents.
Keywords: Chemotherapy induced diarrhea, CPT-11 (irinotecan), diarrhea prevention and control, CPT-11 metabolism, toxicity, antidiarrheals/pharmacology, enzyme inhibitors/pharmacology.
Current Drug Targets
Title:Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case for Prophylaxis
Volume: 14 Issue: 7
Author(s): Umang Swami, Sanjay Goel and Sridhar Mani
Affiliation:
Keywords: Chemotherapy induced diarrhea, CPT-11 (irinotecan), diarrhea prevention and control, CPT-11 metabolism, toxicity, antidiarrheals/pharmacology, enzyme inhibitors/pharmacology.
Abstract: CPT-11 (irinotecan), a DNA topoisomerase I inhibitor is one of the main treatments for colorectal cancer. The main dose limiting toxicities are neutropenia and late onset diarrhea. Though neutropenia is manageable, CPT-11 induced diarrhea is frequently severe, resulting in hospitalizations, dose reductions or omissions leading to ineffective treatment administration. Many potential agents have been tested in preclinical and clinical studies to prevent or ameliorate CPT-11 induced late onset diarrhea. It is predicted that prophylaxis of CPT-11 induced diarrhea will reduce sub-therapeutic dosing as well as hospitalizations and will eventually lead to dose escalations resulting in better response rates. This article reviews various experimental agents and strategies employed to prevent this debilitating toxicity. Covered topics include schedule/dose modification, intestinal alkalization, structural/chemical modification, genetic testing, anti-diarrheal therapies, transporter (ABCB1, ABCC2, BCRP2) inhibitors, enzyme (β-glucuronidase, UGT1A1, CYP3A4, carboxylesterase, COX-2) inducers and inhibitors, probiotics, antibiotics, adsorbing agents, cytokine and growth factor activators and inhibitors and other miscellaneous agents.
Export Options
About this article
Cite this article as:
Swami Umang, Goel Sanjay and Mani Sridhar, Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case for Prophylaxis, Current Drug Targets 2013; 14 (7) . https://dx.doi.org/10.2174/1389450111314070007
DOI https://dx.doi.org/10.2174/1389450111314070007 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry Towards the Management of Inflammation: Recent Developments of mPGES-1 Inhibitors
Recent Patents on CNS Drug Discovery (Discontinued) Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers
Recent Patents on CNS Drug Discovery (Discontinued) Genomics and Proteomics of Nucleoside Transporters
Current Pharmacogenomics Extracellular Vesicles in Glioblastoma: Role in Biological Processes and in Therapeutic Applications
Current Cancer Drug Targets The SCF-type E3 Ubiquitin Ligases as Cancer Targets
Current Cancer Drug Targets Brain Tumor Causes, Symptoms, Diagnosis and Radiotherapy Treatment
Current Medical Imaging Multiple Functions of Rad9 for Preserving Genomic Integrity
Current Genomics A Challenge for Medicinal Chemistry by the 17β-hydroxysteroid Dehydrogenase Superfamily: An Integrated Biological Function and Inhibition Study
Current Topics in Medicinal Chemistry Tumor Dormancy and the Angiogenic Switch: Possible Implications of Bone Marrow- Derived Cells
Current Pharmaceutical Design Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Design, Synthesis, and Biological Evaluation of Novel Thiazolyl Substituted Bis-pyrazole Oxime Derivatives with Potent Antitumor Activities by Selectively Inducing Apoptosis and ROS in Cancer Cells
Medicinal Chemistry From Concept to Reality: The Long Road to c-Met and RON Receptor Tyrosine Kinase Inhibitors for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Variability in Reward Responsivity and Obesity: Evidence from Brain Imaging Studies
Current Drug Abuse Reviews Clinical Pharmacokinetics of Irinotecan-Based Chemotherapy in Colorectal Cancer Patients
Current Clinical Pharmacology Expression and Function of Kruppel Like-Factors (KLF) in Carcinogenesis
Current Genomics NOB1: A Potential Biomarker or Target in Cancer
Current Drug Targets Targeting Plasminogen Activator Inhibitor-1: Role in Cell Signaling and the Biology of Domain-Specific Knock-in Mice
Current Drug Targets Therapeutic Potential of Natural Compounds in Lung Cancer
Current Medicinal Chemistry Anticarcinogenic Actions of Tributyrin, A Butyric Acid Prodrug
Current Drug Targets